Charles River Laboratories (CRL)

NYSE


	Symbol		Exchange		Currency
	CRL		NYSE		USD	Real-time
	CRL		TradeGate		EUR	Delayed

Currency in USD

173.91

-4.17(-2.34%)

Closed08:00:09

After Hours

176.99+3.08(+1.77%)

11:57:39

Fair Value

Day's Range

173.81

182.25

52 wk Range

173.81

275.00

CRL Income Statement

Featured here, the Income Statement (earnings report) for Charles River Laboratories, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

27/12

2015

26/12

2016

31/12

2017

30/12

2018

29/12

2019

28/12

2020

26/12

2021

25/12

2022

31/12

2023

30/12

Total Revenues

2,621.23

2,923.93

3,540.16

3,976.06

4,129.41

Total Revenues Growth

+15.67%

+11.55%

+21.08%

+12.31%

+3.86%

Cost Of Revenues

1,656.2

1,850.39

2,202.69

2,508.4

2,600.23

Gross Profit

965.03

1,073.54

1,337.47

1,467.66

1,529.18

Gross Profit Growth

+14.52%

+11.24%

+24.58%

+9.73%

+4.19%

Gross Profit Margin %

36.82%

36.72%

37.78%

36.91%

37.03%

Other Operating Expenses, Total

577.23

634.47

703.08

801.18

873.01

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+15.34%	+9.92%	+10.82%	+13.95%	+8.97%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	487.69	522.59	578.23	654.61	735.57
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

387.8

439.08

634.39

666.48

656.17

Operating Income Growth

+13.32%

+13.22%

+44.48%

+5.06%

-1.55%

EBIT Margin %

14.79%

15.02%

17.92%

16.76%

15.89%

Net Interest Expenses

-59.36

-85.6

-73.26

-58.51

-131.51

Net Interest Expenses Growth

+5.72%

-44.2%

+14.42%

+20.13%

-124.77%

Interest Expense, Total

-60.88

-86.43

-73.91

-59.29

-136.71

Interest And Investment Income

1.52

0.83

0.65

0.78

5.2

Other Non Operating Expenses, Total

13.48

113.95

-54.46

-91.7

1.15

EBT, Excl. Unusual Items

341.92

467.43

506.67

516.27

525.81

Gain (Loss) On Sale Of Assets

-

-

20

123.41

-0.96

Other Unusual Items, Total

-

-10.3

-

-

98.5

EBT, Incl. Unusual Items

304.08

447.11

480.71

622.99

581.28

EBT, Incl. Unusual Items Growth

+7.95%

+47.04%

+7.51%

+29.6%

-6.69%

EBT, Incl. Unusual Items Margin

11.6%

15.29%

13.58%

15.67%

14.08%

Income Tax Expense

50.02

81.81

81.87

130.38

100.91

Net Income to Company

254.06

365.31

398.84

492.61

480.37

Minority Interest

-2.04

-1

-7.86

-6.38

-5.75

Net Income

252.02

364.3

390.98

486.23

474.62

Net Income Growth

+11.33%

+44.55%

+7.32%

+24.36%

-2.39%

Net Income Margin %

9.61%

12.46%

11.04%

12.23%

11.49%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

252.02

364.3

390.98

486.23

474.62

Basic EPS - Continuing Operations

5.17

7.35

7.77

9.57

9.27

Basic EPS - Continuing Operations Growth

+10.27%

+42.16%

+5.74%

+23.09%

-3.18%

Diluted EPS - Continuing Operations

5.07

7.2

7.6

9.48

9.22

Diluted EPS - Continuing Operations Growth

+10.46%

+42.01%

+5.56%

+24.74%

-2.74%

Basic Weighted Average Shares Outstanding

48.73

49.55

50.29

50.81

51.23

Diluted Weighted Average Shares Outstanding

49.69

50.61

51.43

51.3

51.45

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

585.9

674

899.93

970.35

970.29

EBITDA Growth

+16.25%

+15.04%

+33.52%

+7.83%

-0.01%

EBITDA Margin %

22.35%

23.05%

25.42%

24.4%

23.5%

EBIT